Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein
overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still …

Double hit lymphomas (DHL) represent a subset of highly aggressive B‐cell malignancies
characterized by the presence of recurrent cytogenetic rearrangements affecting MYC and …

MYC translocations are a defining feature of Burkitt lymphoma and a group of diffuse large B-
cell lymphoma (DLBCL) with inferior outcome. However, the clinical relevance of MYC gene …

A central hallmark of cancer cells is the reprogramming of cellular metabolism to meet the
bioenergetic and biosynthetic demands of malignant growth. Here, we report that the miR …

Genomic alterations and protein expression levels have been established as prognostic
factors for survival in patients with diffuse large B‐cell lymphoma (DLBCL). In particular …

Background: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin
lymphoma worldwide. The current standard of care is chemoimmunotherapy with an R …

Composite diffuse large B-cell lymphomas (DLBCLs) with peripheral T-cell lymphomas
(PTCLs) are rare co-occurrences with poorly understood pathologic features. Herein, we …

Objective: Primary central nervous system lymphoma (PCNSL) is a specific type of non-
Hodgkin lymphoma with poor prognosis. The rare incidence of this disease and difficulty to …

Background Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell
lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and …

Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐
line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However …